Cable Hill Partners’s Ovid Therapeutics OVID Stock Holding History

Cable Hill Partners’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,000	Closed	-$6K	–	822
2018 Q3	$6K	Hold	1,000	–	–	﹤0.01%	532
2018 Q2	$8K	Buy	+1,000	New	+$8.58K	﹤0.01%	538

Other funds holding OVID

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Cable Hill Partners's OVID Position: Q4 2018 in Review

Cable Hill Partners sold out of Ovid Therapeutics (OVID) in Q4 2018, closing a stake of 1,000 shares — an estimated $6K sold.

Cable Hill Partners first reported a position in OVID in Q2 2018 and held it in 2 quarters. The position peaked at $8K in Q2 2018. 47 funds tracked by Wall St. Rank hold OVID as of Q4 2018.

Cable Hill Partners reported no remaining Ovid Therapeutics position as of Q4 2018 after selling out during the quarter.
Cable Hill Partners sold 1,000 Ovid Therapeutics shares in Q4 2018, an estimated $6K.
Cable Hill Partners first reported a position in Ovid Therapeutics in Q2 2018 and held it in 2 quarters.
Cable Hill Partners's Ovid Therapeutics position peaked at $8K in Q2 2018.
47 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q4 2018.

Based on Cable Hill Partners's 13F filing for Q4 2018, filed 12 Feb 2019.